R&D Spending Showdown: Zoetis Inc. vs Iovance Biotherapeutics, Inc.

Zoetis vs Iovance: A Decade of R&D Investment

__timestampIovance Biotherapeutics, Inc.Zoetis Inc.
Wednesday, January 1, 20142704597396000000
Thursday, January 1, 201515470000364000000
Friday, January 1, 201628037000376000000
Sunday, January 1, 201771615000382000000
Monday, January 1, 201899828000432000000
Tuesday, January 1, 2019166023000457000000
Wednesday, January 1, 2020201727000463000000
Friday, January 1, 2021259039000508000000
Saturday, January 1, 2022294781000539000000
Sunday, January 1, 2023344077000614000000
Monday, January 1, 2024686000000
Loading chart...

Unleashing the power of data

R&D Spending Trends: Zoetis Inc. vs Iovance Biotherapeutics, Inc.

In the dynamic world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Zoetis Inc. and Iovance Biotherapeutics, Inc. have showcased contrasting R&D investment strategies. From 2014 to 2023, Zoetis consistently outpaced Iovance, with R&D spending peaking at approximately 614 million USD in 2023, a 55% increase from 2014. Meanwhile, Iovance's R&D expenses surged by an impressive 12,600%, reaching around 344 million USD in 2023. This stark contrast highlights Zoetis's steady commitment to innovation, while Iovance's exponential growth reflects its aggressive push in the biotech arena. As these companies continue to evolve, their R&D investments will be pivotal in shaping their future breakthroughs and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025